GlassScriptPhysician profile
Theodore W Wasserman
NPI 1427178821
$8,184.57
in general payments reported to CMS, 2019-2025
19 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $1,007 · 2021: $2,246 · 2022: $1,686 · 2023: $1,093 · 2024: $1,641 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,876 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,875.98 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,423.00 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,248.91 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $974.55 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $792.18 | 2021-2024 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $766.15 | 2019-2024 | Uzedy, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $657.29 | 2019-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $560.00 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $437.63 | 2019-2025 | Invega, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $354.71 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $220.67 | 2019-2021 | |
| Indivior INC. | $193.17 | 2020-2024 | Perseris |
| Noven Therapeutics, LLC | $164.13 | 2020-2022 | |
| Allergan, INC. | $95.88 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $86.27 | 2024 | Invega Sustenna |
| Almatica Pharma LLC | $66.18 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $59.72 | 2021-2023 | Trintellix |
| Validus Pharmaceuticals LLC | $39.61 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $30.08 | 2024 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.